Table 2.
Analysis of the San Francisco Bay Area cohort independently of ethnicity and tumor type (PTC and FTC included).
| Tumors | BRAF mutant | BRAF wild-type | ||||
|---|---|---|---|---|---|---|
| Cases | Controls | OR (95% CI) |
Cases | Controls | OR (95% CI) |
|
|
MC1R consensus |
8 | 15 | reference | 17 | 15 | reference |
| 1 MC1R variant |
21 | 10 | 3.938 (1.2572 to 12.3322) |
34 | 32 | 0.938 (0.4024 to 2.1839) |
| ≥ 2 MC1R variants |
16 | 20 | 1.5 (0.5089 to 4.4213) |
32 | 36 | 0.784 (0.3379 to 1.8202) |
| total | 45 | 45 | p = 0.039* | 83 | 83 | p = 0.810* |
Given are odds ratios for BRAF mutant and BRAF wild-type thyroid carcinoma depending on the number of MC1R variants compared to the matched control cohort.
*
Pearson chi-square test.